Zacks Investment Research upgraded shares of HI TECH PHARMA (HITK) from UNDERPERFORM to NEUTRAL on December 11, 2012, with a target price of $36.50.
Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on HI TECH PHARMA (HITK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment